ClinicalTrials.gg
CompletedNCT03202368Updated Sep 4, 2020

An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

A Phase 3 interventional study of Tocilizumab in Giant Cell Arteritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tocilizumab in Giant Cell Arteritis — 2 open to participants now, 3 under way, 1 of them phase 3. tocilizumab · Giant Cell Arteritis.

Enrollment
12th of 12
3 · median 44
Started
2017
the only one that year
Phase 3
3 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
3 of 12
Hoffmann-La Roche

Among the 12 studies testing tocilizumab in Giant Cell Arteritis, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 3, and was the 3rd registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 49 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

2 of the 12 studies testing tocilizumab in Giant Cell Arteritis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tocilizumab in Giant Cell Arteritis, or all of them as a file.
02

Study summary

This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who subsequently have flare or persisting disease activity. A maximum of 11 participants from six centers in France that participated in the WA28119 study will be enrolled. The entire study duration is anticipated to be approximately 160 weeks.

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed the 156-week WA28119 core study in France
  • Participants who experienced at any time during the WA28119 core study a clinical improvement based on the Investigator's judgment and may continue to benefit from SC tocilizumab in this study
  • Participants whom the investigator wants to treat with SC tocilizumab due to persistent active GCA at the time of completion of the 156-week WA28119 core study and/or new flare occurring within 3 years after completion of the 156-week WA28119 core study

Exclusion criteria

Exclusion Criteria:

  • Participants who have prematurely withdrawn from the WA28119 core study for any reason
  • Participants who had major surgery within 8 weeks prior to screening or planned major surgery within the next 12 months
  • Major ischemic event, unrelated to GCA, within 12 weeks of inclusion
  • Transplanted organs (except corneal transplant performed more than 3 months prior to inclusion)
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies or to prednisone
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), psychiatric, osteoporosis/osteomalacia, glaucoma, corneal ulcers/injuries, or gastrointestinal (GI) disease
  • Current liver disease, as determined by the investigator (positive surface antigen or antibody)
  • History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose a participant to perforations
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of the nail beds)
  • Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of inclusion or oral antibiotics within 2 weeks of inclusion
  • Active TB requiring treatment within the previous 3 years
  • Primary or secondary immunodeficiency (history of or currently active)
  • Evidence of malignant disease or diagnosed since last WA28119 study visit (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that have been excised and cured)
  • Female participants of and female participants who are breastfeeding
  • Male participants of who are not willing to use an effective method of , such as condom, sterilization, or true abstinence throughout study and for a minimum of 6 months after study drug therapy
  • History of alcohol, drug, or chemical abuse within 1 year prior to inclusion
  • Body weight of more than (>) 150 kilograms
  • Treatment with any agent within 12 weeks (or five half-lives of the investigational drug, whichever is longer) of inclusion (except tocilizumab)
  • Previous treatment with cell-depleting therapies including investigational agents, including but not limited to Campath (alemtuzumab), anti-cluster of differentiation (CD) 4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20
  • Treatment with IV gamma globulin or plasmapheresis within 6 months of inclusion
  • Previous treatment with alkylating agents such as chlorambucil or with total lymphoid irradiation
  • Immunization with a live/attenuated vaccine within less than or equal to (≤) 4 weeks prior to inclusion
  • Treatment with hydroxychloroquine, cyclosporine A, azathioprine, or mycophenolate mofetil within 4 weeks of inclusion
  • Treatment with etanercept within 2 weeks; infliximab, certolizumab, golimumab, abatacept, or adalimumab within 8 weeks; or anakinra within 1 week of inclusion
  • Previous treatment with tofacitinib
  • Treatment with cyclophosphamide within 6 months of inclusion
  • Participants requiring systemic for other conditions other than GCA, which, in the opinion of the Investigator, would interfere with the assessments of the protocol
  • Receipt of more than (>) 100 mg daily intravenous methylprednisolone within 6 weeks of inclusion
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Tocilizumab: GCA Flare or Persistent Disease Activity

    Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.

    Drug: Tocilizumab

Interventions

  • 162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first

    Also known as: RO4877533

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with Adverse Events

    Time frame: Baseline up to 160 weeks

Secondary outcomes

  1. Baseline up to 160 weeks

    Time frame: Baseline (Week 0), Weeks 48, 96, 156

  2. Patient Global Assessment of Disease Activity Disease Activity, as Assessed Based on Visual Analogue Scale Score

    Time frame: Baseline (Week 0), Weeks 48, 96, 156

  3. Change from Baseline in Erythrocyte Sedimentation Rate Values

    Time frame: Baseline (Week 0), Weeks 48, 96, 156

  4. Change from Baseline in C-Reactive Protein Values

    Time frame: Baseline (Week 0), Weeks 48, 96, 156

  5. Number of Subjects Who Receive Concomitant Medications With SC Tocilizumab

    Time frame: Baseline up to 156 weeks

  6. Number of SC Tocilizumab Injections Administered

    Time frame: Baseline up to 156 weeks

  7. Total SC Tocilizumab Dose Administered

    Time frame: Baseline up to 156 weeks

  8. Duration of SC Tocilizumab Treatment

    Time frame: Baseline up to 156 weeks

  9. Duration of SC Tocilizumab Interruption

    Time frame: Baseline up to 156 weeks

  10. Duration Between Last Tocilizumab Administration in Study WA28119 and First Tocilizumab Administration in Current Study

    Time frame: From last tocilizumab administration in Study WA28119 to first tocilizumab administration in current study (approximately up to 3 years; assessed retrospectively at Baseline)

07

Study locations

3 sites
  • Hopital La Cavale Blanche; Rhumatologie
    Brest, 29609, France
  • Hopital Claude Huriez; Internal Medicine
    Lille, 59037, France
  • Hopital Emile Muller; Medecine Interne
    Mulhouse, 68070, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Aug 2019, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2017
First posted
Jun 28, 2017
StartActual
Oct 25, 2017
Primary completionActual
Aug 21, 2019
CompletionActual
Aug 21, 2019
Last update
Sep 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03202368
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Oct 25, 2017
Primary completion
Aug 21, 2019
Completion
Aug 21, 2019
Last update
Sep 4, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion